C4X Discovery Holdings PLC (LON: C4XD), a pioneering drug discovery company, today announced its interim results for the six months ended 31 January 2017. Corporate highlights: Strategy · The
C4X Discovery Holdings PLC (LON:C4XD), a pioneering drug discovery company, announced today a proposed conditional placing to raise up to approximately £7.0 million before expenses (the “Placing”) via a placing of
Software developed by Oxford e-Research Centre in collaboration with C4X Discovery Limited and the Mathematical Institute should reduce the time taken to develop new drugs for complex disorders such as
Manchester Science Partnership’s Alderley Park campus has launched an open-access, nuclear magnetic resonance (NMR) facility. Typically, the only way for companies to access NMR spectroscopy equipment has been through academia,
Zeus Capital’s Dr Gary Waanders discusses C4X Discovery Holdings PLC in this exclusive interview with DirectorsTalk
C4X Discovery Holdings Plc (LON:C4XD) is the topic of discussion with Dr Gary Waanders, Healthcare Research Director at Zeus Capital. Gary, runs through the important highlights from the latest results
Commenting on the strategic collaboration, Clive Dix, CEO of C4X Discovery, commented: “We are delighted to expand on our successful relationship with Evotec through this alliance that is designed to
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
